Compare · MRNA vs NVIV
MRNA vs NVIV
Side-by-side comparison of Moderna Inc. (MRNA) and InVivo Therapeutics Holdings Corp (NVIV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRNA and NVIV operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $64.66B, about 5099.9x NVIV ($12.7M).
- MRNA has hit the wire 8 times in the past 4 weeks while NVIV has been quiet.
- MRNA has more recent analyst coverage (25 ratings vs 0 for NVIV).
- Company
- Moderna Inc.
- InVivo Therapeutics Holdings Corp
- Price
- $50.74-3.98%
- $0.32-34.04%
- Market cap
- $64.66B
- $12.7M
- 1M return
- -5.22%
- -
- 1Y return
- +84.64%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- News (4w)
- 8
- 0
- Recent ratings
- 25
- 0
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
InVivo Therapeutics Holdings Corp
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). The company is developing a Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord to treat acute SCI. InVivo Therapeutics Holdings Corp. was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.
Latest MRNA
- Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate
- Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting
- Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19
- Moderna to Present at Upcoming Conferences in May 2026
- Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026 AACR Annual Meeting
- Moderna to Report First Quarter 2026 Financial Results on Friday, May 1, 2026
- Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026
- SEC Form 4 filed by Mock James M
- Amendment: SEC Form SCHEDULE 13G/A filed by Moderna Inc.
- SEC Form DEF 14A filed by Moderna Inc.
Latest NVIV
- SEC Form SC 13G/A filed by InVivo Therapeutics Holdings Corp (Amendment)
- SEC Form SC 13G/A filed by InVivo Therapeutics Holdings Corp (Amendment)
- 12 Health Care Stocks Moving In Monday's After-Market Session
- Why Big Lots Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Monday's Mid-Day Session
- 12 Health Care Stocks Moving In Monday's Intraday Session
- 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- Why Disney Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
- Foose Brice sold $123,030 worth of InVivo Therapeutics Holdings Corp (330,000 units at $0.37), closing all direct ownership in the company (SEC Form 4) (Amendment)
- Foose Brice closing all direct ownership in the company (SEC Form 4)
- InVivo Therapeutics Holdings shares are trading higher amid volatility after the company previously filed for relief under the provisions of Chapter 11.